The improved tumour to non-tumour ratios needed for effective tumour targeting with antibodies requires that blood background radioactivity is reduced. We investigated the effect of streptavidin as a clearing agent for '25l-labelled biotinylated anti-CEA antibodies in a human colon carcinoma xenograft model. By comparing the biodistribution of the monoclonal antibody A5B7 with four, nine or 22 biotins per antibody molecule, we investigated how the degree of biotinylation of the primary radiolabelled antibody affects its clearance with streptavidin. Limiting the degree of biotinylation limited blood clearance, whereas nine or 22 biotins per antibody molecule resulted in a 13-to 14-fold reduction in blood radioactivity, the streptavidinbiotinylated antibody complexes clearing rapidly via the liver and spleen. Although a reduction in tumour activity was also seen, a 6.6-fold improvement in the tumour to blood ratio was achieved. A comparative study of streptavidin versus second antibody clearance was carried out using the polyclonal antibody PK4S biotinylated with 12 biotins per antibody molecule. This study indicated that second antibody was superior for clearance of the polyclonal antibody, resulting in a larger and faster reduction in blood radioactivity and improved tumour to blood ratios. In this case the primary antibody was polyclonal, and therefore nonuniformity of biotinylation may affect complexation with streptavidin. Therefore, the degree of biotinylation and type of antibody must be carefully considered before the use of streptavidin clearance.
Radioimmunotargeting is limited by the persistence of radiolabelled antibody in the circulation, which results in low tumour to blood ratios. This slow antibody clearance from the blood and non-target tissues delays the time at which imaging can be carried out, and also therapy is limited by the potential damage to normal tissues.
To alleviate this problem various clearing strategies have been used to reduce blood background levels. Investigations into the administration of a second antibody reactive with the first, anti-tumour, antibody have been carried out in animals (Keep et al., 1983; Sharkey et al., 1984 Sharkey et al., , 1988 Pedley et al., 1989) and in man (Begent et al., 1982 (Begent et al., , 1987 Goldenberg et al., 1987) , in whom efficient clearing of the immune complexes formed in the blood is achieved via the reticuloendothelial system. Another method involves the use of biotinylated anti-tumour antibodies with avidin (or streptavidin) administered as the clearing agent. This system utilises the very high affinity of avidin (and streptavidin) for biotin (Ka = 10-15 M-) (Green, 1970) and also the fast clearance of avidin-complexed biotinylated antibodies (Sinitsyn et al., 1989) . Avidin-biotin schemes have been used in various two-step (Kalofonos et al., 1990; Paganelli et al., 1992; Khawli et al., 1993) and three-step pretargeting strategies (Paganelli et al., 1990a (Paganelli et al., , 1991 when the radiolabel is administered separately. Utilisation of avidin as a clearing agent for circulating radiolabelled biotinylated antibodies during radioimmunotargeting of tumours has been reported as a case report for a colorectal cancer patient (Paganelli et al., 1990b) . However, the clearance pattern and effects on tumour localisation to evaluate the clinical use of clearing radiolabelled biotinylated antibodies for radioimmunotherapy have not been reported.
We have carried out a detailed investigation into the use of streptavidin as a clearing agent for a radiolabelled biotinylated anti-CEA antibody, and its effect on tumour localisation and distribution in normal tissues. We have investigated whether in vivo distribution and clearance depend on the biotinylation reaction by comparing forms of the monoclonal anti-CEA antibody A5B7 with differing degrees of biotinylation in the mouse LS174T colonic tumour xenograft model. We have also carried out a comparative study to evaluate whether a streptavidin clearance system is superior to second antibody clearance. This study involved the use of the polyclonal anti-CEA antibody PK4S with donkey anti-sheep as the second antibody, in comparison with the biodistribution obtained from biotinylated PK4S cleared with streptavidin.
Materials and methods
Antibody preparation and radiolabelling Antibodies used were A5B7, a monoclonal murine anti-CEA , and PK4S (PK2G), a polyclonal sheep anti-CEA . Various biotinylation reactions with these anti-tumour antibodies were carried out as follows:
Caproylamidobiotin-NHS ester (Sigma, Poole, UK) in DMSO (5 mg ml-') was added to A5B7 (1 mg ml-' in 0. (Green, 1965 (Tom et al., 1976) . Both A5B7 and PK4S antibodies have been shown to localise with this tumour model (Pedley et al., 1991 (Figure 1 ), resulting in a 40% reduction in blood radioactivity compared with controls lacking streptavidin. A reduction in both the normal and tumour tissue radioactivity was seen in a similar proportion to the decrease in blood activity, and therefore no improvement in the tumour to blood ratio was achieved.
Increasing biotinylation of the primary antibody dramatically increased the clearing effect of streptavidin. radioactivity in the liver and the spleen as the immune comr plexes are taken up. At 24 h after streptavidin administration (48 h after antibody injection) a 14-fold reduction in blood radioactivity levels to 0.8% I D g-1, in comparison with control animals, was achieved, as shown in Figure 2b Although tumour radioactivity was also reduced, from app roximately 24% to 9% I D g-', the resulting tumour tc blood ratio is greatly improved from 2.2 to 14.5, as shown ir Table I .
To determine the effect of further increasing the biotinyla tion of the primary antibody, the biodistribution of A5B, with 22 biotins per antibody molecule was investigated. A difference between these two latter biotinylated antibodies wa seen 1 h after the streptavidin injection, when a larger decreasc in blood radioactivity was seen with the more heavily bio tinylated antibody (Figure 3a) together with a concomitan large increase in spleen and liver radioactivity levels on clear ing the complexes formed. Blood radioactivity levels at 11 after streptavidin injection for the A5B7 with 22 biotins wa: only 3% I D g-', which is 57% less than the blood radioactivity obtained with the A5B7 with nine biotins, showing that the more heavily biotinylated primary antibody was cleared from the circulation faster after administration of streptavidin. Figure 3b shows that 24 h after streptavidin administration the biodistribution of the A5B7 with 22 biotins is very similar to that of the A5B7 with nine biotins (Figure 2b) . A 13-fold reduction of primary antibody in the circulation to 0.7% I D g-I was achieved and the tumour radioactivity was reduced 2.3 times to 8.4% I D g-1, therefore greatly increasing the tumour to blood ratio from 2.4 to 15.9 (Table I) .
Comparison of streptavidin clearance with second antibody clearance
It
As no second antibody to A5B7 was available, and because a general anti-mouse antibody cannot be used with a mouse h model, the comparative streptavidin versus second antibody S clearance study was carried out using the polyclonal sheep antibody PK4S. PK4S biotinylated to 12 biotins per antibody molecule was studied as the primary radiolabelled antitumour antibody with streptavidin clearance. Figure 4 shows the effect on biodistribution when streptavidin is administered 24 h after primary biotinylated antibody injection. Clearance via the liver and spleen again resulted in a 4.5-fold reduction in blood radioactivity to 1.4% I D g-' 24 h after streptavidin administration. Tumour radioactivity was also reduced in a similar proportion and therefore no significant improvement in tumour to blood ratio was observed.
The comparative study with second antibody clearance gave the results shown in Figure 5 . By 1 h after second antibody administration a 3.2-fold reduction and by 24 h a 13.5-fold reduction of the primary antibody in the blood was seen. A 3.8-fold decrease in tumour radioactivity resulted, and thus an improvement in tumour to blood ratio from 1.5 to 5.6 was achieved 24 h after second antibody injection.
With the exception of the A5B7 with four biotins, all the clearing strategies used have resulted in increased levels of radioactivity in the liver and spleen. By 24 h after the clearing agent the radioactivity in the liver had decreased to below control values but splenic radioactivity levels never became less than those of the controls.
Discussion
We have shown that clearance of circulating biotinylated primary antibody can be achieved with the administration of streptavidin. The degree of biotinylation of the antibody must be optimised in order to obtain the most favourable tumour to non-tumour ratios.
We have shown that if the level of biotinylation of A5B7 is limited, then the blood clearance is limited, accompanied by a similar decrease in tumour radioactivity (Figure 1) , thus no beneficial increase in tumour to non-tumour ratios is achieved.
When biotinylation of A5B7 was increased to nine or 22 biotins per antibody molecule a 6.6-fold improvement in tumour to blood ratio resulted 24 h after streptavidin administration (Table I) . With the more heavily biotinylated A5B7 (22 biotins per antibody molecule) a greater decrease in circulatory radioactivity was seen 1 h after streptavidin than that seen with the A5B7 with nine biotins. This faster clearance is thought to occur because the greater availability of biotin on ASB7 with 22 biotins per antibody molecule means that larger immune complexes can be formed with the streptavidin, and they can be expected to clear faster than smaller complexes. This is a favourable result with respect to reducing the risk of myelotoxicity in radioimmunotherapy caused by prolonged retention of radioactivity in the blood, but the resultant large increase in the liver and splenic uptake is undesirable. Twenty-four hours after streptavidin administration these levels are reduced to near-control radioactivity levels in the spleen and less than control values for the liver. Although myelotoxicity, which is reported as the doselimiting toxicity in patients (Ettinger et al., 1982) , would be reduced, further time points to evaluate the dose to the spleen need to be studied in order to evaluate possible splenic toxicity. The spleen is a less radiosensitive organ than the bone marrow, and therefore this high, but possibly transient, activity may present only a minor problem.
The ability of avidin to clear biotinylated antibodies from the circulation was first reported by Sinitsyn et al. (1989) , who showed an increase in liver and splenic uptake of biotinylated antibody-avidin complexes, which is in agreement with our data. A preliminary study for radioimmunoguided surgery by Paganelli et al. (1990b) showed that avidin administration after radiolabelled biotinylated antibody injection resulted in successful blood clearance in a patient, although the radioactivity level in other tissues was not reported. Avidin has also been used successfully by Norrgren et al. (1993) Work by Paganelli et al. (1990a Paganelli et al. ( , 1991 has been carried out to improve tumour targeting by using cold biotinylated antibodies to tar'get the tumour followed by clearance with avidin or streptavidin before administration of the biotinconjugated radiolabel (three-step pretargeting). Although improved tumour to non-tumour ratios have been reported, this method involves a more complicated protocol to ensure correct timings of injections in order to achieve the optimal dose.
It is important to assess whether clearance with streptavidin finproves on second antibody clearance. Results from our comparative second antibody versus streptavidin study indicate that the second antibody clearance system was superior, as improved tumour to blood ratios resulted (5.6 for second antibody clearance compared with 2.0 for streptavidin clearance). The reduction in blood radioactivity levels seen with streptavidin clearance was not as large, or as fast, as the clearance seen with second antibody, where blood radioactivity was reduced 13.5-fold 24h after second antibody administration (Figure 5b ). However, this may be because the primarv antibodyv in this casep wvas polyclonnal and therefore not uniformly biotinylated (some molecules may have little or no biotin attached), thus a proportion of the radiolabelled antibody was unable to complex with streptavidin and clear, leaving a residual amount of primary antibody in the circulation. On the present evidence streptavidin is not the preferred system for the clearance of poly-clonal antibodies, and in this situation second antibody clearance would be more advantageous. A direct comparison with monoclonal antibodies was not possible, but streptavidin does have the advantage of being applicable to antibodies of different types and to antibody fragments. Both second antibody and streptavidin are likely to be immunogenic in man, but the use of immunosuppressive drugs may overcome this (Ledermann et al. (1988) .
We have shown that streptavidin clearance of primary biotinylated monoclonal antibody will give preferential tumour to blood ratios important for radioimmunotherapy (Table I) . Unfortunately, in all the streptavidin clearance strategies carried out the radioactivity associated with the tumour was reduced, which was also seen with second antibody clearing strategies by Pedley et al. (1989) and Sharkey et al. (1988) . Although absolute tumour uptake values are decreased, this can be overcome by increasing the dose of radioactivity initially injected, thus ensuring tumour radioactivity remains high enough after clearance for effective therapy while blood levels are reduced to minimise myelotoxicity. This was shown by Blumenthal et al. (1989) , who demonstrated that, in a comparative study of radiolabelled primary antibody alone and primary antibody at double the dose plus second antibody clearance, the latter gave improved therapy but without any increase in toxicity.
Biotinylation is a mild procedure (Bayer & Wilchek, 1990) and should be universally applicable to most monoclonal antibodies as the biotin NHS-ester incorporates via lysine residues which are numerous in most proteins. Although the biotinylated antibodies used for this series of experiments had reduced amounts of biotin after radiolabelling with chloramine T, radiolabelling of biotinylated antibodies has now been carried out using lodo-gen (Fraker & Speck, 1978) . We have found that this gentler method of radiolabelling with iodine does not have an adverse effect on the biotins conjugated to the protein and is therefore recommended for any future iodinations of biotinylated antibodies. We are therefore encouraged that biotinylation and streptavidin clearance of A5B7 and other monoclonal anti-tumour antibodies can be optimised and successfully used in the clinic. 
